RISK OF THROMBOSIS IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA: A POPULATION-BASED COHORT STUDY
EHA Learning Center, Anna Maria Birgisdottir, 181729
QUADRUPLET VS SEQUENTIAL TRIPLET INDUCTION THERAPY FOR MYELOMA PATIENTS: RESULTS OF THE MYELOMA XI STUDY.
EHA Learning Center, Charlotte Pawlyn, 181694
NIVOLUMAB FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS TRANSPLANT: FULL RESULTS AFTER EXTENDED FOLLOW-UP OF THE MULTICOHORT MULTICENTER PHASE 2 CHECKMATE 205 TRIAL
EHA Learning Center, Andreas Engert, 181699
YOU DON'T KNOW JAK: A PROGRAMMED RIBOSOMAL FRAMESHIFTING DEFECT POTENTIATES THE TRANSFORMING ACTIVITY OF THE JAK2-V617F MUTATION
EHA Learning Center, Sergey SULIMA, 181704
DASATINIB IN CHILDREN AND ADOLESCENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) FROM A PHASE 2 TRIAL
EHA Learning Center, C.M. Zwaan, 181709
ETO2-GLIS2 RECRUITS ETO2/ERG COMPLEX AT SUPER-ENHANCERS TO CONTROL TRANSCRIPTION AND DRIVE LEUKEMIC PROPERTIES IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA
EHA Learning Center, Cecile Thirant, 181714
THE COMBINATION OF ORAL ALL-TRANS RETINOIC ACID AND DANAZOL VS DANAZOL AS SECOND-LINE TREATMENT IN ADULT IMMUNE THROMBOCYTOPENIA: A MULTICENTRE, RANDOMIZED, OPEN-LABEL TRIAL
EHA Learning Center, Xiao-Hui Zhang, 181718
THE YING AND YANG OF JAK SIGNALING : LOSS OF USP9X BUFFERS JAK SIGNALING AND ENHANCES SURVIVAL OF CRLF2-JAK-STAT EXPRESSING B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA.
EHA Learning Center, Omer Schwartzman, 181723
ASSESSING THE RISK-BENEFIT OF ANTICOAGULANTS IN ELDERLY PATIENTS WITH CANCER-ASSOCIATED VENOUS THROMBOEMBOLISM: A POPULATION BASED STUDY
EHA Learning Center, Alejandro Lazo-Langner, 181728
CYTOSOLIC NUCLEIC ACID SENSORS PROMOTE INTESTINAL EPITHELIALINTEGRITY DURING ACUTE TISSUE DAMAGE AND PROTECT FROM GRAFT-VERSUS-HOST DISEASE
EHA Learning Center, Hendrik Poeck, 181733
EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY
EHA Learning Center, Rachael F Grace, 181738
AML Treatment Beyond 3+7
EHA Learning Center, Norbert Vey, 184474
Fertility preservation in pre-pubertal and adolescent males
EHA Learning Center, Rod Mitchell, 184479
Controversies in treating small clots in the leg and in the lung
EHA Learning Center, Sebastian Schellong, 184487
CRISPR/Cas9 genome editing, from mechanism to therapy
EHA Learning Center, Jacob Corn, 184491
Fertility Preservation In Female Patients
EHA Learning Center, Marie-Madeline Dolmans, 184478
Targeting Mutated FLT3
EHA Learning Center, Mark Levis, 184473
What patients expect from hematologists
EHA Learning Center, A Plate, 184477
Novel aspects in the diagnostic management of deep vein thrombosis and pulmonary embolism
EHA Learning Center, Menno Huisman, 184486
Towards clinical translation of targeted gene editing in human hematopoietic stem cells
EHA Learning Center, Luigi Naldini, 184490
France-Belgium-Switzerland: The GRAALL Intergroup
EHA Learning Center, Herve Dombret, 184481
Molecular Diagnostics In AML
EHA Learning Center, Lars Bullinger, 184472
The effects of chemotherapy and radiotherapy on reproduction
EHA Learning Center, William Hamish Wallace, 184476
Major results and future approaches of Italian ALL study groups
EHA Learning Center, Sabina Chiaretti, 184480
Cross-talk between inflammation and coagulation
EHA Learning Center, Thomas Renné, 184485
Circulating tumor DNA in Non-Hodgkin lymphoma: Clinical and future research applications
EHA Learning Center, Mark Roschewski, 184470
How to treat CML in 2017
EHA Learning Center, Andreas Hochhaus, 184454
GVL And GVHD Differences And Similarities
EHA Learning Center, Fred Falkenburg, 184458
Neurological complications of sickle cell disease
EHA Learning Center, Fenalla Kirkham, 184462
Rare bleeding disorders - Diagnosis and treatment
EHA Learning Center, Gili Kenet, 184466
Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess
EHA Learning Center, Josee Zijlstra, 184469
Do we still need bone marrow biopsies?
EHA Learning Center, Tarec El-Galaly, 184468
Molecular work up and monitoring of CML patients
EHA Learning Center, Nick Cross, 184453
The Role Of Intestinal Flora In Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
EHA Learning Center, Marcel van den Brink, 184457
Iron Chelation In Hemoglobinopathies
EHA Learning Center, Vip Viprakasit, 184461
Diagnosis and management of DIC and primary hyperfibrinolysis
EHA Learning Center, Alessandro Squizzato, 184465
Introduction EHA LyG
EHA Learning Center, M.J. Kersten, 184467
Novel approaches to eradicate CML stem cells
EHA Learning Center, Mhairi Copland, 184452
GvHD Prophylaxis And Treatment, New Modalities
EHA Learning Center, Robert Zeiser, 184456
Genome editing in hemoglobinopathies
EHA Learning Center, Mitch Weiss, 184460
Biological and clinical relevance of fibrin clot structure
EHA Learning Center, Nicola Mutch, 184464
Fertility preservation in females
EHA Learning Center, Marie-Madeline Dolmans, 192906
OUTCOME OF PATIENTS WITH INTRAVASCULAR B-CELL LYMPHOMA, A RETROSPECTIVE STUDY CONDUCTED ON BEHALF OF THE LYMPHOMA STUDY ASSOCIATION (LYSA) GROUP
EHA Learning Center, Antoine BONNET, 181504
OUTCOME OF ELDERLY DLBCL PATIENTS (≥ 80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY
EHA Learning Center, Marek Trneny, 181505
IMPROVED SURVIVAL IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL) UP TO AGE 70 ONLY: A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL IN THE NETHERLANDS, 1989-2015
EHA Learning Center, Avinash Dinmohamed, 181506
CLINICAL AND GENETIC DIVERSITY IN DIAMOND-BLACKFAN ANAEMIA: AN UPDATE FROM THE UNITED KINGDOM
EHA Learning Center, Deena Iskander, 181520
BONE MARROW FAILURE SECONDARY TO NOVEL/KNOWN PRIMARY IMMUNODEFICIENCY-RELATED MUTATIONS. A SINGLE CENTER ANALYSIS
EHA Learning Center, Maurizio Miano, 181521
COVERSIN, A NOVEL C5 COMPLEMENT INHIBITOR, FOR THE TREATMENT OF PNH: RESULTS OF A PHASE 2 CLINICAL TRIAL
EHA Learning Center, Anita Hill, 181522
GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Jennifer Brown, 181523
RESULTS OF A PHASE II MULTICENTER STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE IN PTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Learning Center, Alexey Danilov, 181536
RELATIVE SURVIVAL REACHES A PLATEAU IN HAIRY CELL LEUKEMIA (HCL): A POPULATION-BASED STUDY ON INCIDENCE, PRIMARY TREATMENT AND SURVIVAL AMONG 1,427 PATIENTS DIAGNOSED IN THE NETHERLANDS, 1989-2014
EHA Learning Center, Avinash Dinmohamed, 181537
CUMULATIVE ILLNESS RATING SCALE (CIRS) PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI): AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG
EHA Learning Center, Valentin Goede, 181538
A PHASE II RANDOMISED STUDY INVESTIGATING THE EFFICACY OF STANDARD OR HIGH-DOSE OFATUMUMAB IN COMBINATION WITH CHEMOTHERAPY IN RELAPSED CHRONIC LYMPHOCYTIC LEUKAEMIA
EHA Learning Center, david allsup, 181539
MULTISCALE IMAGE-BASED QUANTITATIVE ANALYSIS OF BONE MARROW STROMAL NETWORK TOPOLOGY REVEALS STRICT SPATIAL CONSTRAINTS FOR HEMATOPOIETIC-STROMAL CELLULAR INTERACTIONS
EHA Learning Center, Cesar Nombela Arrieta, 181553
TEMPLATED V(D)J INSERTIONS ARE A NOVEL BIOLOGIC MECHANISM FOR B-CELL RECEPTOR REPERTOIRE DIVERSIFICATION
EHA Learning Center, Marvyn Koning, 181554
TARGETING THE CASPASE / NOX2 AXIS TO MODULATE MACROPHAGE POLARIZATION
EHA Learning Center, Stephanie Solier, 181555
MULTIPLE MYELOMA-POLARIZED M2C MACROPHAGES PROMOTE A TUMOR-SUPPORTIVE OSTEOLYTIC MICROENVIRONMENT VIA CXCL13
EHA Learning Center, Katia Beider, 181556
GENOTYPING OF HODGKIN LYMPHOMA ON THE LIQUID BIOPSY
EHA Learning Center, Valeria Spina, 181569
FDG PET-CT MAYBE A USEFUL TOOL TO IDENTIFY DOXORUBICIN INDUCED CARDIOTOXICITY IN HODGKIN LYMPHOMA
EHA Learning Center, Eleonora Arboscello, 181570
ELEVATED SYSTEMIC HEME AND IRON LEVELS AS RISK FACTORS FOR VASCULAR DYSFUNCTION AND ATHEROSCLEROSIS: EVIDENCE FROM B-THALASSEMIA AND HEMOCHROMATOSIS COHORT STUDIES
EHA Learning Center, Francesca Vinchi, 181571
REAL-WORLD ADHERENCE TO IRON CHELATION THERAPY: COMPARING A FILM-COATED TABLET VERSUS DISPERSIBLE TABLET OF DEFERASIROX
EHA Learning Center, Qayyim Said, 181572
XPO1 INHIBITION SYNERGIZES WITH BCR INHIBITION, BLOCKS TUMOR GROWTH AND PROLONGS SURVIVAL IN A BIOLUMINESCENT ANIMAL MODEL OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Marta Crespo, 181585
MOLECULAR HETEROGENEITY IN PERIPHERAL T-CELL LYMPHOMA NOT OTHERWISE SPECIFIED REVEALED BY COMPREHENSIVE MUTATIONAL PROFILING.
EHA Learning Center, Yosaku Watatani, 181586
A COMPREHENSIVE PORTRAIT OF THE DNA METHYLOME OF 866 SAMPLES FROM DIFFERENT B CELL NEOPLASMS: BIOLOGICAL INSIGHTS AND CLINICAL APPLICATIONS
EHA Learning Center, Martí Duran-Ferrer, 181587
ACTIVATION OF RHOA-VAV1 SIGNALING AXIS IN ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA
EHA Learning Center, Manabu Fujisawa, 181588
UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
EHA Learning Center, Guillermo Montalban-Bravo, 181602
AZACITIDINE IMPROVES OUTCOME IN HIGH RISK MDS PATIENTS WITH CHROMOSOME 7 ABNORMALITIES: RETROSPECTIVE COMPARISON OF GESMD AND GFM REGISTRIES.
EHA Learning Center, Félix López Cadenas, 181603
Phase II Study OPN-305, a (TLR-2) Antibody, in patients with lower risk myelodysplastic syndromes with prior hypomethylating agent (HMA) therapy
EHA Learning Center, Guillermo Montalban-Bravo, 181604
IN PATIENTS UNDEGOING HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MDS DEVELOPMENT OF CHRONIC GVHD COULD AMELIORATE THE ADVERSE IMPACT OF SPECIFIC SOMATIC MUTATIONS
EHA Learning Center, Félix López Cadenas, 181605
PROGNOSTIC IMPLICATIONS OF MULTIPLE CYTOGENETIC HIGH-RISK ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Moritz Binder, 181618
LENALIDOMIDE MAINTENANCE VS PLACEBO AFTER STEM CELL TRANSPLANT FOR PATIENTS WITH MULTIPLE MYELOMA: OVERALL SURVIVAL AND PROGRESSION-FREE SURVIVAL AFTER ADJUSTING FOR TREATMENT CROSSOVER IN CALGB
EHA Learning Center, Philip L. McCarthy, 181619
UPDATED RESULTS FROM ASPIRE AND ENDEAVOR, RANDOMISED, OPEN-LABEL, MULTICENTRE PHASE 3 STUDIES OF CARFILZOMIB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Roman Hajek, 181620
EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (DRD) VERSUS RD ALONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED ANALYSIS OF POLLUX
EHA Learning Center, Meletios A. Dimopoulos, 181621
A STUDY OF UTILITY OR FUTILITY OF PERFORMING SKELETAL SURVEYS IN PARAPROTEINAEMIA: A MULTICENTER EXPERIENCE FROM UK
EHA Learning Center, Ovini GAMAGE, 181634
SERUM FLC MEASUREMENTS COMPLEMENT BONE MARROW ASSESSMENT TO DETERMINE PROGNOSIS IN MYELOMA PATIENTS ACHIEVING DEEP RESPONSES
EHA Learning Center, Thomas Dejoie, 181635
THE CONNECT MM REGISTRY: IMPACT OF THE CYTOGENETIC ABNORMALITY T(11;14) ON SURVIVAL OUTCOMES IN AFRICAN AMERICAN AND NON-AFRICAN AMERICAN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Cristina J. Gasparetto, 181636
A DECREASED INTRACELLULAR S1P LEVEL AND S1P RECEPTORS EXPRESSED ON MEGAKARYOCYTES POSSIBLY CONTRIBUTE TO DEFECTIVE PROPLATELETS FORMATION IN IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Xiao-Hui Zhang, 181650
ANTIBODY MEDIATED GLYCAN MODIFICATION: A POTENTIAL ROLE IN PLATELET DESTRUCTION IN AUTOIMMUNE THROMBOCYTOPENIA
EHA Learning Center, Irene Marini, 181651
NOVEL RUNX1 MUTATIONS IN FAMILIES WITH INHERITED THROMBOCYTOPENIA
EHA Learning Center, Patrizia Noris, 181652
DO PHYSICIANS NEED HELP TO ADEQUATELY INFORM AND SUPPORT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA? RESULTS FROM A QUALITATIVE STUDY IN GREECE
EHA Learning Center, Aliki XOCHELLI, 181665
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH ACUTE LEUKEMIA ABOVE 70 YEARS OF AGE: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT
EHA Learning Center, Jonathan Canaani, 181666
BLOOD BAALC AND MN1 COPY NUMBER ASSESSMENT BY DIGITAL DROPLET PCR PRIOR TO ALLOGENEIC TRANSPLANTATION PREDICTS RELAPSE IN ACUTE MYELOID LEUKEMIA PATIENTS
EHA Learning Center, Madlen Jentzsch, 181667
THE USE OF BPX-501 DONOR T CELL INFUSION (WITH INDUCIBLE CASPASE 9 SUICIDE GENE) TOGETHER WITH HLA-HAPLOIDENTICAL STEM CELL TRANSPLANT TO TREAT CHILDREN WITH HEMOGLOBINOPATHIES AND ERYTHROID DISORDERS
EHA Learning Center, Alice Bertaina, 181668
VALIDATING A NOVEL CAPILLARY ELECTROPHORESIS: THE MOST SUITABLE PLATFORM FOR THE NATIONAL NEWBORN SCREENING PROGRAM IN A REGION WITH HIGH PREVALENCE OF THALASSEMIA AND HEMOGLOBINOPATHIES
EHA Learning Center, thidarat suksangpleng, 181682
TRANSIENT ELASTOGRAPHY IN NON TRANSFUSION DEPENDENT THALASSEMIA: A SUCCESSFUL TOOL TO ASSESS AND MONITORING LIVER FIBROSIS
EHA Learning Center, Alessia Marcon, 181683
INCREASING INCIDENCE OF MALIGNACIES IN AGING THALASSEMIC PATIENTS: A SINGLE INSTITUTION'S LONGITUDINAL EXPERIENCE
EHA Learning Center, Elpida REPOUSI, 181684
TARGETED SINGLE CELL SEQUENCING TO IDENTIFY MUTATIONAL HIERARCHY IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jolien De Bie, 181438
RESULTS FROM UKALL60+, A UK/HOVON COLLABORATIVE PHASE 2 STUDY IN ELDERLY PATIENTS WITH UNTREATED ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Learning Center, Nick Morley, 181451
CLINICAL OUTCOMES OF ELDERLY ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA - A SINGLE INSTITUTION EXPERIENCE
EHA Learning Center, Kevin Miller, 181452
MANAGEMENT AND OUTCOME OF ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED AT THE “SAPIENZA” UNIVERSITY BETWEEN 1996 AND 2016
EHA Learning Center, Sabina Chiaretti, 181453
THE TETRASPANIN CD9 IS A PROGNOSTIC MARKER FOR PREDICTING SURVIVAL OUTCOMES OF PEDIATRIC B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Kam Tong Leung, 181454
STROMA-DERIVED FACTORS STIMULATE JAK/STAT SIGNALING IN AML CELLS RESULTING IN RESISTANCE TO BCL2 INHIBITOR VENETOCLAX
EHA Learning Center, Riikka Karjalainen, 181468
IDENTIFICATION OF NOVEL GENE FUSIONS IN ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING
EHA Learning Center, Frank Rücker, 181469
H3K27ME3 LEVEL ON THE HIST1 CLUSTER: A POWERFUL EPIGENETIC BIOMARKER THAT STRATIFIES TWO GROUPS OF NPM1-MUTATED AML DIFFERING IN THEIR OUTCOME AND EXPRESSION PROFILE
EHA Learning Center, Sylvain garciaz, 181470
FUNCTIONAL ASSESSMENT OF NOVEL DIAGNOSTIC FLT3 MUTATIONS AND INHIBITION BY KINASE INHIBITORS
EHA Learning Center, Katherine Tarlock, 181471
EXPERIENCE WITH MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN AML WITH RUNX1-RUNX1T1: A STUDY ON 186 PATIENTS
EHA Learning Center, Alexander Höllein, 181486
NUMBER OF TP53 ABNORMALITIES AND THEIR CLINICAL RELEVANCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Guillermo Montalban-Bravo, 181487
VADASTUXIMAB TALIRINE PLUS HYPOMETHYLATING AGENTS (HMA): A WELL-TOLERATED REGIMEN WITH HIGH REMISSION RATE IN FRONTLINE OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, Farhad Ravandi-Kashani, 181488
ACUTE MYELOID LEUKEMIA WITH INTERMEDIATE-RISK CYTOGENETICS AND A FAVORABLE GENOTYPE: PROGNOSTIC FACTORS AND RESULTS IN PATIENTS TREATED ACCORDING THE SPANISH CETLAM PROTOCOLS.
EHA Learning Center, Jorge Sierra, 181489
DIFFERENTIATION SYNDROME ASSOCIATED WITH ENASIDENIB (AG-221), A SELECTIVE INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE 2 (MIDH2)
EHA Learning Center, Amir T. Fathi, 181502